Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 20vPnC in Adults 60-64 Years
NCT03313037Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Prevnar 20 in pneumococcal infection, sponsored by Pfizer. Started Oct 2017; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03313037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313037.